These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 7886308

  • 1. Myeloma and related disorders.
    Kyle RA, Durie BG, Boccadoro M, Pavlovsky S.
    Rev Invest Clin; 1994 Apr; Suppl():46-51. PubMed ID: 7886308
    [No Abstract] [Full Text] [Related]

  • 2. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
    Pileri A, Barbui T, Boccadoro M, Comotti B, Dammacco F, Gallamini A, Marmont F, Neretto G, Petrucci MT, Resegotti L.
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554
    [No Abstract] [Full Text] [Related]

  • 3. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S, Fonseca R, Lacy M, Witzig T, Lust J, Greipp P, Therneau T, Kyle R, Litzow M, Gertz M.
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [Abstract] [Full Text] [Related]

  • 4. Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation.
    Hájek R, Adam Z, Vásová I, Král Z.
    Acta Med Austriaca; 1996 Sep; 23(3):85-91. PubMed ID: 8798281
    [Abstract] [Full Text] [Related]

  • 5. Advances in the treatment of multiple myeloma.
    Barlogie B, Jagannath S, Tricot G, Desikan KR, Fassas A, Siegel D.
    Adv Intern Med; 1998 Sep; 43():279-320. PubMed ID: 9506186
    [No Abstract] [Full Text] [Related]

  • 6. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
    Gertz MA, Lacy MQ, Inwards DJ, Chen MG, Pineda AA, Gastineau DA, Greipp PR, Lust JA, Tefferi A, Witzig TE, Kyle RA, Litzow MR.
    Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
    [Abstract] [Full Text] [Related]

  • 7. [Multiple myeloma--new therapeutic perspectives].
    Skotnicki AB, Wolska-Smoleń T, Jurczyszyn A.
    Przegl Lek; 1999 Feb; 56 Suppl 1():67-72. PubMed ID: 10494186
    [Abstract] [Full Text] [Related]

  • 8. [Plasmocytic pleural effusion disclosing multiple myeloma].
    Elloumi M, Frikha M, Masmoudi H, Mseddi S, Ben Ayed M, Bouaziz M, Makni F, Souissi T.
    Rev Mal Respir; 2000 Apr; 17(2):495-7. PubMed ID: 10859769
    [Abstract] [Full Text] [Related]

  • 9. Effect of complete response on outcome following autologous stem cell transplantation for myeloma.
    Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA, Larson D, Therneau TM, Kyle RA, Litzow MR, Greipp PR, Gertz MA.
    Bone Marrow Transplant; 2000 Nov; 26(9):979-83. PubMed ID: 11100277
    [Abstract] [Full Text] [Related]

  • 10. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D, Cao Y, Luetkens T, Panse J, Faltz C, Arfsten J, Bartels K, Wolschke C, Eiermann T, Zander AR, Fehse B, Bokemeyer C, Kroger N.
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [Abstract] [Full Text] [Related]

  • 11. [High-dose melphalan in patients with multiple myeloma].
    Moreau P, Le Bonniec M, Harousseau JL.
    Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
    [Abstract] [Full Text] [Related]

  • 12. [Nonproducing myeloma without evident bone lesion].
    Kawatani T, Maeda N, Hosoda A, Agou H, Nakai K, Kawasaki H.
    Rinsho Ketsueki; 1990 Jun; 31(6):842-6. PubMed ID: 2214175
    [Abstract] [Full Text] [Related]

  • 13. [Multiple myeloma. Biological, prognostic, and therapeutic aspects].
    Corrado C, Pavlovsky S.
    Sangre (Barc); 1990 Aug; 35(4):289-97. PubMed ID: 1703328
    [No Abstract] [Full Text] [Related]

  • 14. [Monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma].
    Schleiffenbaum BE.
    Praxis (Bern 1994); 2012 Nov 28; 101(24):1521-9; quiz 1530-1. PubMed ID: 23184544
    [No Abstract] [Full Text] [Related]

  • 15. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome.
    Patriarca F, Damiani D, Fanin R, Grimaz S, Geromin A, Cerno M, Sperotto A, Silvestri F, Zaja F, Baccarani M.
    Haematologica; 2000 Mar 28; 85(3):269-74. PubMed ID: 10702815
    [Abstract] [Full Text] [Related]

  • 16. [New trends in the therapy of myeloma].
    Jantunen E, Nousiainen T.
    Duodecim; 2000 Mar 28; 116(9):937-9. PubMed ID: 11988994
    [No Abstract] [Full Text] [Related]

  • 17. Cutaneous involvement in multiple myeloma and bortezomib.
    Siniscalchi A, Fratoni S, Santeusanio G, Del Poeta G, de Fabritiis P, Caravita T.
    Ann Hematol; 2009 Nov 28; 88(11):1137-9. PubMed ID: 19259673
    [No Abstract] [Full Text] [Related]

  • 18. [Multiple myeloma--advances in disease biology and implications for therapy].
    Chou T.
    Gan To Kagaku Ryoho; 2001 Sep 28; 28(9):1206-12. PubMed ID: 11579631
    [Abstract] [Full Text] [Related]

  • 19. [Diagnosis and therapy of multiple myeloma: current aspects].
    Betticher DC, Cerny T, Fey MF.
    Schweiz Med Wochenschr; 1995 Mar 18; 125(11):541-51. PubMed ID: 7899848
    [Abstract] [Full Text] [Related]

  • 20. [Not Available].
    Hitz F.
    Praxis (Bern 1994); 2016 Mar 18; 105(21):1255-1260. PubMed ID: 28573955
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.